Immutep (IMMP) Competitors $1.94 -0.07 (-3.48%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.97 +0.03 (+1.49%) As of 05/21/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. CALT, BGM, AMPH, ETNB, AUPH, GYRE, MLYS, WVE, PAHC, and ARDXShould you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Calliditas Therapeutics AB (publ) (CALT), Qilian International Holding Group (BGM), Amphastar Pharmaceuticals (AMPH), 89bio (ETNB), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), Mineralys Therapeutics (MLYS), Wave Life Sciences (WVE), Phibro Animal Health (PAHC), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Immutep vs. Calliditas Therapeutics AB (publ) Qilian International Holding Group Amphastar Pharmaceuticals 89bio Aurinia Pharmaceuticals Gyre Therapeutics Mineralys Therapeutics Wave Life Sciences Phibro Animal Health Ardelyx Immutep (NASDAQ:IMMP) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Do institutionals & insiders have more ownership in IMMP or CALT? 2.3% of Immutep shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 3.1% of Immutep shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to IMMP or CALT? In the previous week, Immutep had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Immutep and 0 mentions for Calliditas Therapeutics AB (publ). Immutep's average media sentiment score of 0.12 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Immutep is being referred to more favorably in the media. Company Overall Sentiment Immutep Neutral Calliditas Therapeutics AB (publ) Neutral Is IMMP or CALT more profitable? Immutep has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Immutep's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets ImmutepN/A N/A N/A Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has higher earnings and valuation, IMMP or CALT? Immutep has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmutep$5.14M55.12-$28.01MN/AN/ACalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the MarketBeat Community prefer IMMP or CALT? Immutep received 285 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 72.56% of users gave Immutep an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformImmutepOutperform Votes31272.56% Underperform Votes11827.44% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Which has more risk and volatility, IMMP or CALT? Immutep has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Do analysts recommend IMMP or CALT? Immutep presently has a consensus price target of $7.00, indicating a potential upside of 260.82%. Calliditas Therapeutics AB (publ) has a consensus price target of $39.25, indicating a potential downside of 1.88%. Given Immutep's stronger consensus rating and higher probable upside, analysts clearly believe Immutep is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immutep 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryImmutep beats Calliditas Therapeutics AB (publ) on 14 of the 16 factors compared between the two stocks. Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricImmutepPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$283.32M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / Sales55.12250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book1.856.466.794.50Net Income-$28.01M$143.98M$3.23B$248.18M7 Day Performance6.01%3.04%4.07%1.14%1 Month Performance28.48%7.44%12.52%15.18%1 Year Performance-39.94%-2.46%16.83%6.55% Immutep Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPImmutep1.4058 of 5 stars$1.94-3.5%$7.00+260.8%-39.9%$283.32M$5.14M0.002,021Gap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180BGMQilian International Holding GroupN/A$12.18-2.9%N/AN/A$1.18B$25.10M0.00298Positive NewsGap UpAMPHAmphastar Pharmaceuticals4.2439 of 5 stars$24.79-0.3%$32.33+30.4%-42.4%$1.18B$730.66M8.261,620ETNB89bio2.7432 of 5 stars$7.70-1.0%$26.43+243.2%+7.4%$1.12BN/A-2.6540Positive NewsAUPHAurinia Pharmaceuticals2.4223 of 5 stars$8.07-1.5%$11.50+42.5%+49.2%$1.09B$247.30M-53.80300GYREGyre Therapeutics0.281 of 5 stars$11.11-2.1%N/A-20.8%$1.04B$100.64M555.5040MLYSMineralys Therapeutics2.7508 of 5 stars$15.32-0.2%$38.00+148.0%+29.0%$998.48MN/A-4.2128Gap DownWVEWave Life Sciences4.367 of 5 stars$6.46+2.1%$21.17+227.7%-4.4%$995.71M$104.94M-5.82240Positive NewsGap DownPAHCPhibro Animal Health3.5339 of 5 stars$24.13+0.5%$20.00-17.1%+26.6%$978.09M$1.19B50.271,860Positive NewsARDXArdelyx4.4931 of 5 stars$4.06+4.6%$10.39+155.9%-48.3%$971.38M$361.71M-25.3890Insider Trade Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives Qilian International Holding Group Alternatives Amphastar Pharmaceuticals Alternatives 89bio Alternatives Aurinia Pharmaceuticals Alternatives Gyre Therapeutics Alternatives Mineralys Therapeutics Alternatives Wave Life Sciences Alternatives Phibro Animal Health Alternatives Ardelyx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
